中国agreementsDesignExamination GuidePatent Law
2023年1月4日

FOLLOW UP: Amendments to the China Patent Examination Guidelines in 2022 – Part 1: New rules for designs in view of China signing onto the Hague Agreement

by
黄惠盈女士
黄幸儿女士
车李晓芸女士

Since the publication of our earlier article about China signing onto the Hague Agreement, some of our Hong Kong clients have expressed interest in taking advantage of the Hague international design application system, i.e., filing a Hague international design application with the CNIPA (Chinese National Intellectual Property Administration) as a receiving office (RO).

Up until this moment, the World Intellectual Property Organization (WIPO) and the CNIPA1 have been silent on whether a Hong Kong design applicant without a habitual residence or business office in mainland China would be eligible to file a Hague international design application with the CNIPA as a RO.

We recently brought this matter forward to the CNIPA. The CNIPA confirmed that Hong Kong applicants without a habitual residence or business office in mainland China are not eligible to file such type of application with the CNIPA.

A Hague application currently does not cover Hong Kong nor Macao

Although China is included in the current list of the contracting parties of the Hague Agreement, Hong Kong SAR and Macao SAR – both separate jurisdictions having distinct Basic Laws from the People Republic of China – are not included.

This means that Hong Kong and Macao design applicants must file independent design applications in these two regions.

Despite the current situation, things may change in the future. China’s “instrument of accession” (legal document indicating China’s agreement to join the Hague Agreement) provides room for change, stating that the current situation stands “until otherwise notified by the Government of the People’s Republic of China”2. This means that China has already included provisions allowing it to provide notification of changes regarding Hong Kong and Macao in the future.

Stay tuned for more upcoming articles about the other changes in the proposed Patent Examination Guidelines.

This article is for general informational purposes only and should not be considered legal advice or a legal opinion on a specific set of facts.

  1. https://www.wipo.int/hague/en/
    https://www.wipo.int/hague/memberprofiles/selectmember#/
    https://www.wipo.int/hague/en/news/2022/news_0005.html
    https://www.wipo.int/treaties/en/notifications/hague/treaty_hague_146.html
    https://wipolex.wipo.int/en/treaties/ShowResults?search_what=C&treaty_id=9
    https://www.cnipa.gov.cn/col/col2893/index.html
    https://www.cnipa.gov.cn/art/2022/10/31/art_75_180016.html
    https://www.cnipa.gov.cn/module/download/downfile.jsp?classid=0&showname=附件1:《专利审查指南修改草案(再次征求意见稿)》修改对照表.pdf&filename=dab071af523943b49eaf1114a84b6234.pdf ↩︎
  2. https://www.wipo.int/hague/en/news/2022/news_0005.html ↩︎

其他文章

Foreign companies transferring IP out of China: things to know

2018年10月25日
Inventions made in China Most foreign companies with R&D sites in China are aware of the fact that inventors having inventions made in China have to obtain permission before they can file patent applications outside of China for these Chinese inventions. It doesn’t matter if the owner of the business is a foreign entity. Patent […]

IP Strategies for the Newly Released Implementation Regulations of the 4th Amendment of the Chinese Patent Law: Part 2: Grace Period without Loss of Novelty

2024年2月7日
Background As mentioned in our earlier article, the Implementation Regulations of the Chinese Patent Law (“Regulations”, similar to the CFR in the US) were approved in November, and the CNIPA finally made public the full text of the Regulations just before the arrival of the New Year. At the same time, the CNIPA also released […]

First ever Invalidation decision on an RNAi Invention patent in China

2023年12月4日
Decision on Examination of Request for Invalidation (No. 58530) In one of China’s Top 10 Patent Re-examination / Invalidation cases of 2022, an invalidation decision on a patent claiming Hepatitis B Virus (HBV) RNAi compositions (No. 58530) by the Patent Re-examination Board (the “Board”) sheds light on the standard for post filing data for rejections […]

US vs CN: Foreign Filing License Requirements

2022年11月9日
In China, foreign filing requirements are generally very similar to the US — a foreign filing license is required if a foreign application is to be filed first for an invention made in the country. The Chinese equivalent to the US foreign filing license is called a confidentiality examination for foreign filing. According to Chinese […]

我们的过去活动

Top crossarrow-right